What is Vertex Pharmaceuticals's net change in cash?

Vertex Pharmaceuticals (VRTX) reported net change in cash of $417.1M in Q1 2026.

How has Vertex Pharmaceuticals's net change in cash changed year-over-year?

Vertex Pharmaceuticals's net change in cash increased by 268.5% year-over-year, from $113.2M to $417.1M.

What is the long-term trend for Vertex Pharmaceuticals's net change in cash?

Over 2 years (2022 to 2025), Vertex Pharmaceuticals's net change in cash has grown at a -61.5% compound annual growth rate (CAGR), from $3.71B to $549.8M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Vertex Pharmaceuticals VRTX Net Change in Cash

Net Change in Cash at other companies

Lexicon PharmaceuticalsLXRX

$3.76M+200%

Travere Therapeutics, Inc.TVTX

-$14.67M-536%

Agios PharmaceuticalsAGIO

$24.47M+801%

AbbVieABBV

$4.16B+1,293%

4D Molecular TherapeuticsFDMT

$12.25M+177%

Beam TherapeuticsBEAM

-$6.64M-103%

Other financials

Income statement

See full

Revenue$3.0B+7.8%

Gross profit$2.6B+7.8%

Operating income$1.1B+80.6%

Net income$1.0B+59.6%

EPS (diluted)$4.02+61.4%

Balance sheet

See full

Cash & equivalents$5.5B+17.5%

Total debt$2.0B+20.5%

Total equity$19.4B+17.4%

Total assets$26.5B+15.8%

Cash flow

See full

Operating cash flow$1.4B+74.4%

CapEx$133.4M+228%

Free cash flow$1.3B+66.4%

Valuation

See full

Market cap$124.7B+7.8%

Enterprise value$121.19B+8.0%

P/E28.8×—

P/S10.2×+0.1×

Profitability

See full

Gross margin86.2%+0.2pp

Operating margin38.3%—

Net margin35.5%—

FCF margin30.4%+20.2pp

Returns & leverage

See full

Return on equity24.2%—

Debt / equity0.1×0.0×

Current ratio3×+0.4×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vertex Pharmaceuticals's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vertex Pharmaceuticals's net change in cash?: Vertex Pharmaceuticals (VRTX) reported net change in cash of $417.1M in Q1 2026.
How has Vertex Pharmaceuticals's net change in cash changed year-over-year?: Vertex Pharmaceuticals's net change in cash increased by 268.5% year-over-year, from $113.2M to $417.1M.
What is the long-term trend for Vertex Pharmaceuticals's net change in cash?: Over 2 years (2022 to 2025), Vertex Pharmaceuticals's net change in cash has grown at a -61.5% compound annual growth rate (CAGR), from $3.71B to $549.8M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.